GUANGZHOU, China, May 15, 2026 /PRNewswire/ — Pomdoctor Limited (“Pomdoctor” or the “Company”) (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced its financial results for the fiscal year ended December 31, 2025.

Mr. Zhenyang Shi, Chairman and Chief Executive Officer of Pomdoctor, commented: “Fiscal year 2025 marked a year of solid revenue expansion and continued execution of our growth strategy. Both our net revenues and gross profit recorded solid year-over-year increases, by 16.7% and 9.6% respectively, primarily driven by the strong growth of our Internet hospital business, particularly online pharmacy sales as we deepened collaboration with pharmaceutical manufacturers. At the same time, we achieved a steady gross margin over 13%, reflecting our capability in maintaining profit while continuing expansion of our business scale, executing sales promotions and obtaining new customers.

“During the year, we also increased our investments in research and development (“R&D”) by 328.5% to support our long-term strategic priorities. Our R&D efforts are focused on enhancing our technology-driven healthcare capabilities and strengthening our platform infrastructure, which we believe will enable us to deliver more efficient and accessible healthcare services while supporting sustainable growth over time.

“Despite the net loss for the year, which was primarily attributable to significant non-recurring expenses associated with our initial public offering, including professional service fees and investor relations initiatives, we view these costs as necessary and strategic investments. These investments enabled our transition to a publicly listed company, strengthened our corporate governance, enhanced our operational and financial capabilities, and unlocked broader growth opportunities for the future. Following our successful listing, we are now better positioned to access capital market resources to support business expansion and execute our long-term growth strategy more efficiently on a larger scale.

“Looking ahead, we remain confident in the long-term growth potential of China’s digital healthcare market. We will continue to deepen strategic partnerships with pharmaceutical companies to further drive Internet hospital growth, accelerate the integration of our platform with online medical insurance systems across major cities, and advance our strategic upgrade centered on ‘artificial intelligence (AI) + medical-grade smart wearables + full-cycle chronic disease management.’ We believe these initiatives will strengthen our ecosystem and position us for scalable growth and long-term value creation.”

Fiscal Year 2025 Financial Summary

• Net revenues were RMB399.9 million (US$57.2 million) in fiscal year 2025, an increase of 16.7% from RMB342.6 million in fiscal year 2024.
• Gross profit was RMB52.3 million (US$7.5 million) in fiscal year 2025, an increase of 9.6% from RMB47.7 million in fiscal year 2024.
• Gross margin was 13.1% in fiscal year 2025, compared to 13.9% in fiscal year 2024.
• Net loss was RMB130.9 million (US$18.7 million) in fiscal year 2025, compared to RMB37.4 million in fiscal year 2024.
• Basic and diluted loss per share were RMB21.96 (US$3.14) in fiscal year 2025, compared to RMB22.72 in fiscal year 2024.

Fiscal Year 2025 Financial Results

Net Revenues

Net revenues were RMB399.9 million (US$57.2 million) in fiscal year 2025, an increase of 16.7% from RMB342.6 million in fiscal year 2024.

• Net revenues from Internet hospital were RMB150.7 million (US$21.6 million) in fiscal year 2025, an increase of 69.3% from RMB89.0 million in fiscal year 2024. The increase was primarily due to the increase in revenues generated from online pharmacy sales. In fiscal year 2025, the Company deepened cooperation with pharmacy manufacturers to sell their products through its Internet hospital platform, which led to that revenue from the Company’s online pharmacy sales increased from RMB87.8 million in fiscal year 2024 to RMB149.2 million (US$21.3 million) in fiscal year 2025. Revenue from online consultation service slightly increased from RMB1.2 million in fiscal year 2024 to RMB1.5 million (US$0.2 million) in fiscal year 2025.
• Net revenues from pharmaceutical supply chain were RMB249.2 million (US$35.6 million) in fiscal year 2025, a decrease of 1.7% from RMB253.5 million in fiscal year 2024, primarily driven by the decrease in the Company’s pharmacy wholesale business from RMB246.9 million in fiscal year 2024 to RMB243.2 million (US$34.8 million) in fiscal year 2025, as a result of the Company’s stable pharmaceutical supply chain business and reduction cooperation with the customers whose credit terms were relatively longer than others. Because of high competition of retail pharmacy store, two of the Company’s retail sales stores were closed in fiscal year 2025, which led to that the revenues from pharmacy retail sales also decreased from RMB6.6 million in fiscal year 2024 to RMB6.0 million (US$0.9 million) in fiscal year 2025.

Cost of Revenues

Cost of revenue was RMB347.6 million (US$49.7 million) in fiscal year 2025, an increase of 17.9% from RMB294.9 million in fiscal year 2024. The increase was primarily due to the increase in cost of revenues in online pharmacy sales from RMB51.0 million in fiscal year 2024 to RMB101.4 million (US$14.5 million) in fiscal year 2025, which was in line with the increase in the Company’s net revenues from Internet hospital. The cost of revenues in pharmaceutical supply chain increased from RMB243.9 million in fiscal year 2024 to RMB246.2 million (US$35.2 million) in fiscal year 2025.

Gross Profit and Gross Margin

Gross profit was RMB52.3 million (US$7.5 million) in fiscal year 2025, an increase of 9.6% from RMB47.7 million in fiscal year 2024.

Gross margin was 13.1% in fiscal year 2025, slightly decreased from 13.9% in fiscal year 2024.

• Gross profit margin of Internet hospital was 32.7% in fiscal year 2025, decreased from 42.7% in fiscal year 2024. The decrease mainly attributable to the increase in the online pharmacy sales of products with lower gross profit margin.
• Gross profit margin of pharmaceutical supply chain was 1.2% in fiscal year 2025, decreased from 3.8% in fiscal year 2024. The decrease was primarily because the gross profit margin of the Company’s pharmacy wholesale customers newly obtained in fiscal year 2025 was lower than that of customers in fiscal year 2024.

Operating Expenses

Total operating expenses were RMB170.9 million (US$24.4 million) in fiscal year 2025, compared to RMB73.5 million in fiscal year 2024.

• Sales and marketing expenses were RMB96.2 million (US$13.8 million) in fiscal year 2025, increased by 70.7% from RMB56.4 million in fiscal year 2024. The increase primarily due to the increase in professional service fees paid to outsourced consultants for promoting the Company’s brand and internet medical platform of approximately RMB36.5 million (US$5.2 million) and service fees to doctors and staff costs which is in line of the increase in the revenues from Internet hospital business.
• General and administrative expenses were RMB59.7 million (US$8.5 million) in fiscal year 2025, increased by 402.9% from RMB11.9 million in fiscal year 2024. The increase primarily due to (i) increase in professional service fee paid to outsourced consultants for consultancy for investor relationship management of approximately RMB38.0 million (US$5.4 million) incurred in fiscal year 2025; and (ii) the increase in consulting service fee and office fees of RMB6.5 million (US$0.9 million) paid during the process of initial public offering, primarily offset by the decrease in expected credit loss recognized resulting from the efforts for collection of accounts receivable.
• Research and development expenses were RMB12.9 million (US$1.8 million) in fiscal year 2025, increased by 328.5% from RMB3.0 million in fiscal year 2024. The increase primarily due to a new research and development project, especially in AI and healthcare-related AI applications, launched in fiscal year 2025 and related consulting service fee paid.
• Impairment loss on property and equipment and operating lease right-of-use assets with definite lives of RMB2.2 million and RMB2.1 million (US$0.3 million) in fiscal year 2024 and 2025, respectively.

Net Loss

Net loss was RMB130.9 million (US$18.7 million) in fiscal year 2025, compared to RMB37.4 million in fiscal year 2024.

Basic and Diluted Loss per Share

Basic and diluted loss per share were RMB21.96 (US$3.14) in fiscal year 2025, compared to RMB22.72 in fiscal year 2024.

Financial Condition

As of December 31, 2025, the Company had cash and cash equivalents of RMB9.6 million (US$1.4 million), compared to RMB7.7 million as of December 31, 2024.

Net cash used in operating activities in fiscal year 2025 was RMB148.5 million (US$21.2 million), compared to RMB16.1 million in fiscal year 2024.

Net cash used in investing activities in fiscal year 2025 was RMB1.6 million (US$0.2 million), compared to RMB0.03 million in fiscal year 2024.

Net cash provided by financing activities in fiscal year 2025 was RMB153.9 million ($22.0 million), compared to RMB17.0 million in fiscal year 2024.

Exchange Rate Information

This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars are made at a rate of RMB6.9931 to US$1.00, the rate set forth in the H.10 statistical release of the U.S. Federal Reserve Board on December 31, 2025.

Recent Development

On October 9, 2025, the Company completed its initial public offering (the “Offering”) of 5,000,004 American Depositary Shares (“ADSs”) at a public offering price of US$4.00 per ADS. On October 10, 2025, the underwriter of the Offering fully exercised its over-allotment option to purchase an additional 750,000 American Depositary Shares of the Company at the public offering price of US$4.00 per ADS. The gross proceeds were US$23,000,016 from the Offering, before deducting underwriting discounts and commissions, and other expenses. The Company’s ADSs began trading on the Nasdaq Global Market on October 8, 2025 under the ticker symbol “POM.”

About POMDOCTOR LIMITED

POMDOCTOR LIMITED is a leading online medical services platform for chronic diseases in China, ranking sixth on China’s Internet hospital market based on the number of contracted doctors in 2022, according to Frost & Sullivan. Focusing on chronic disease management and pharmaceutical services, the Company offers a one-stop platform for medical services, organically connecting patients with doctors and pharmaceutical products. The Company’s operations primarily include Internet hospital and pharmaceutical supply chain, connecting users, pharmacies, suppliers, medical professionals, and other healthcare participants. Through this model, POMDOCTOR aims to enhance the efficiency and transparency of the healthcare value chain. The Company’s mission is to provide effective prevention and treatment solutions to alleviate patients’ sufferings from illnesses. Its vision is to become the most trustworthy medical and healthcare services platform. For more information, please visit the Company’s website: http://ir.7shiliu.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s filings with the SEC.

For more information, please contact:

POMDOCTOR LIMITED
Investor Relations Department
Email: ir@7lk.com

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

POMDOCTOR LIMITED
CONSOLIDATED BALANCE SHEETS

POMDOCTOR LIMITED
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

POMDOCTOR LIMITED
CONSOLIDATED STATEMENTS OF CASH FLOWS

NEW YORK, May 15, 2026 /PRNewswire/ — High-Trend International Group (Nasdaq: HTCO, the “Company”) today announced that it has completed the cancellation and retirement of 630,000 Class A ordinary shares (the “Pre‑Delivery Shares”) that were previously issued to Streeterville Capital, LLC (“Streeterville”) pursuant to a securities purchase agreement dated October 29, 2025.

HTCO Chairman Mr. Christopher Nixon Cox stated that this transaction will help further optimize the Company’s capital structure, reduce potential dilution and provide greater flexibility for the execution of its future business strategy.

Previously, the Company had entered into a payoff acknowledgment and termination agreement with Streeterville, under which the Company fully satisfied all obligations arising from the related financing and received the return of the Pre‑Delivery Shares. Following the completion of the relevant share return and transfer procedures, all 630,000 Pre‑Delivery Shares have now been cancelled and retired, resulting in a corresponding reduction of 630,000 in the number of the Company’s issued and outstanding Class A ordinary shares.

About High-Trend International Group

High-Trend International Group is a global ocean transportation company with core businesses in international shipping.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws, including Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, made under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements can be identified by words such as “believe,” “expect,” “anticipate,” “future,” “will,” “intend,” “plan,” “estimate” or similar expressions. Actual results may differ materially from those indicated by these forward-looking statements due to various risks and uncertainties, including but not limited to those detailed in the Company’s filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this release, and the Company undertakes no obligation to update any forward-looking statement, except as required by applicable law.

WASHINGTON, May 15, 2026 /PRNewswire/ — DeepQure, a clinical-stage medical device company, announced the completion of its featured presentation at the American Urological Association (AUA) Innovation Nexus Forum, held during the AUA Annual Meeting. DeepQure was selected to present the clinical progress of HyperQure™, the world’s first minimally invasive (laparoscopic/robotic) extravascular renal denervation (RDN) system.

The Innovation Nexus Forum is a premier platform for featuring cutting-edge urological technologies. DeepQure was invited to present its unique approach to treating uncontrolled hypertension, which addresses the inherent limitations of conventional catheter based intravascular RDN to address anatomical diversity and achieve full denervation.

While conventional intravascular RDN systems are now commercially available, variable blood pressure reduction due to incomplete or inconsistent nerve ablation remains as a significant unmet challenge. HyperQure™ is engineered to address this inherent limitation by enabling direct, circumferential ablation of perivascular nerves from outside the artery, independent of vessel anatomy.

Expanding Global Clinical Momentum

During the forum, DeepQure reported clinical milestones across its international programs:

• Clinical Status: Successfully completed 15 cases in two early-phase studies — Korea’s first-in-human trial and the US Early Feasibility Study (IDE).
• Institutional Participation: US clinical trials are currently conducted at leading academic centers, including Stanford University, Mayo Clinic, Emory University, UC Irvine, University of Florida, and Henry Ford Health System.
• KOL Participation: DeepQure’s network of global authorities in hypertension includes Drs. David Kandzari and Herbert Aronow, recently bolstered by Professor Raymond Townsend (Medtronic’s SPYRAL HTN lead investigator) to ensure clinical integrity for upcoming trials.
• Safety Profile: No device-related major adverse events (MAEs) have been reported. All patients are in the follow-up stage, with full clinical data scheduled to be presented at EuroPCR 2026 in May.

“The AUA Innovation Nexus Forum provided a critical stage to demonstrate how our extravascular, circumferential approach addresses the therapeutic gap in current RDN treatments,” said Chanho Park, Chairman of the Board of DeepQure. “With 15 cases completed across Korea and the US, the company is now focused on advancing its global pivotal trial.“

About the AUA Innovation Nexus Forum

The AUA Innovation Nexus Forum provides a collaborative venue for showcasing emerging technologies and transformative innovations in urology. The forum connects medical device innovators with global clinical experts to accelerate the development of solutions that address significant unmet needs in urological and related healthcare fields.

About Uncontrolled Hypertension and RDN

Uncontrolled hypertension affects an estimated ~30% of hypertensive patients globally and is associated with a significantly elevated risk of stroke and heart failure. It is clinically defined as systolic blood pressure that remains above 140mmHg despite pharmacological treatment. RDN is an interventional therapy designed to lower blood pressure by disrupting overactive sympathetic nerves surrounding the renal arteries.

About DeepQure

DeepQure is a clinical-stage medtech company developing next-generation RDN treatments. Its lead product, HyperQure™, is a proprietary extravascular system designed for 360° circumferential ablation of renal nerves from outside the vessel. HyperQure holds the Korean MFDS Breakthrough Device Designation and ISO 13485 certification.

We are advised by New York Stock Exchange that journalists and other readers should disregard the news release, NYSE Content Update: Blackstone Digital Infrastructure Debuts for Trade after $1.8 Billion IPO, issued 14-May-2026 over PR Newswire.

SHENZHEN, China, May 14, 2026 /PRNewswire/ — MicroAlgo Inc. (the “Company” or “MicroAlgo”) (NASDAQ: MLGO), today announced the proposal of a powerful solution—a multi-objective evolutionary search strategy, which is an innovative automated tool that can assist in designing quantum circuits, thereby bringing breakthroughs to quantum algorithm development.

The Multi-Objective Evolutionary Algorithm (MOEA) is a class of optimization algorithms based on evolution, specifically designed to address problems involving multiple conflicting objectives. Its working principle mimics the process of natural selection by randomly generating a set of candidate solutions in the solution space and, through iterative processes across multiple generations, continuously improving the quality of solutions through operations such as crossover, mutation, and selection. Ultimately, this evolutionary process can generate a solution set with higher fitness, i.e., optimal solutions that satisfy multiple objectives.

The innovation of the Multi-Objective Evolutionary Algorithm technology developed by MicroAlgo lies in its ability to automatically design quantum circuits from “zero.” In other words, this technology does not require a pre-defined specific circuit design but instead gradually constructs quantum circuits capable of achieving the target functionality by combining search and optimization methods with a universal library of quantum circuit components.

One of the key features of MicroAlgo’s algorithm is its task-universal library. This library contains a large number of different quantum circuit components, whose combinations and parameterization can construct circuits that implement complex functions. This design approach means that developers do not need to manually design circuits; instead, the algorithm automatically searches for the optimal circuit configuration based on the input/output requirements of the task.

More importantly, this algorithm is not only capable of designing circuits but also, through its multi-objective characteristics, can balance trade-offs among various performance metrics. For example, during the design process, the algorithm considers not only the accuracy of the quantum circuit but also other critical metrics such as the circuit’s width, depth, and the number of gates used. This is particularly important for the current stage of quantum computing hardware development, as first-generation quantum processors are extremely limited in resources (such as the number of gates and qubits), and the algorithm must achieve optimal performance within these limited resources.

To validate the effectiveness of the multi-objective evolutionary algorithm, MicroAlgo applied it to the automated design of classic quantum algorithms. Specifically, the Quantum Fourier Transform and Grover’s Search Algorithm were selected as test cases. The Quantum Fourier Transform is a widely used transformation in quantum computing, playing a significant role in many algorithms, such as Shor’s factorization algorithm. Meanwhile, Grover’s Search Algorithm is considered another foundational algorithm in quantum computing, capable of finding target data in an unsorted dataset at a faster speed than classical search algorithms.

In these two tests, the multi-objective evolutionary algorithm was able to find circuit structures that meet the input/output mapping requirements of these algorithms by combining components from the quantum circuit component library. After multiple iterations, the algorithm not only discovered textbook-style classic quantum circuit designs but also found alternative structures that achieve the same functionality. This demonstrates that the algorithm has the capability to efficiently design quantum circuits and can provide multiple alternative circuit solutions, offering great flexibility for the optimization of quantum computing algorithms.

The technical implementation behind the multi-objective evolutionary algorithm involves several key steps and processes. First, in the initial stage, the algorithm generates a set of random quantum circuits. These circuits are composed of quantum components from the library and include adjustable parameters. Subsequently, the algorithm simulates each quantum circuit and evaluates its performance. The evaluation metrics include the circuit’s accuracy, the number of gates used, the circuit’s width, and its depth.

Next, the algorithm filters and optimizes the circuits based on these metrics. Through crossover operations (similar to genetic recombination in biological evolution), the algorithm “crosses” two high-performing circuits to generate new candidate circuits; through mutation operations, the algorithm randomly modifies certain parts of the circuits to introduce new design possibilities. This process is repeated continuously, with each generation eliminating poorly performing circuits while retaining and optimizing high-performing circuits until the optimal solution is found.

The core advantage of the multi-objective evolutionary algorithm lies in its ability to optimize multiple metrics simultaneously. For example, in quantum computing, circuit depth and accuracy are often conflicting objectives: deeper circuits may offer higher accuracy but increase the complexity of execution and hardware requirements. Through this algorithm, developers can find the optimal balance point between these objectives, ensuring that the circuit meets the demands of efficient computation while being implementable under existing hardware conditions.

The multi-objective evolutionary algorithm developed by MicroAlgo is not only a significant technical breakthrough but also has the potential to change the development direction of the quantum computing industry in multiple ways.

First, the introduction of automated tools greatly reduces the difficulty of quantum algorithm development. Currently, the barrier to quantum computing development is high, typically requiring experts with deep backgrounds in quantum physics, quantum information science, and computer science to design effective quantum algorithms. However, with this multi-objective evolutionary algorithm, developers only need to define the objectives of the computational task, and the algorithm can automatically generate circuit designs that meet the requirements, thereby lowering the technical barriers to quantum algorithm development.

Second, this algorithm significantly enhances the efficiency and quality of quantum algorithms. Traditional quantum algorithm design relies on the experience and intuition of experts, whereas this evolutionary algorithm can explore a broader design space, even discovering optimization solutions that humans might not easily find. Especially on resource-constrained quantum hardware, this algorithm can find optimal solutions for different tasks, effectively improving the computational performance of the hardware.

Finally, the multi-objective evolutionary algorithm paves the way for future applications of quantum computing. As quantum computing gradually moves from the laboratory to practical applications, automated tools will become increasingly important. The technology developed by MicroAlgo is not only suitable for existing quantum computing tasks but also capable of addressing the more complex application demands of the future. Whether in fields such as chemical simulation, financial risk analysis, or cryptography, the design of quantum algorithms can be significantly enhanced through this evolutionary algorithm.

The multi-objective evolutionary algorithm represents a major breakthrough in quantum algorithm development. By combining a task-universal library, automated design, and multi-objective optimization, this algorithm not only simplifies the quantum circuit design process but also improves the efficiency and flexibility of circuits. The introduction of this technology marks a new stage in quantum computing, providing a solid foundation for the widespread application of quantum computers across multiple industries. In the future, as quantum hardware continues to advance, there is reason to believe that this multi-objective evolutionary algorithm will have an even more profound impact in the field of quantum computing and drive the emergence of more breakthrough achievements.

About MicroAlgo Inc.

MicroAlgo Inc. (the “MicroAlgo”), a Cayman Islands exempted company, is dedicated to the development and application of bespoke central processing algorithms. MicroAlgo provides comprehensive solutions to customers by integrating central processing algorithms with software or hardware, or both, thereby helping them to increase the number of customers, improve end-user satisfaction, achieve direct cost savings, reduce power consumption, and achieve technical goals. The range of MicroAlgo’s services includes algorithm optimization, accelerating computing power without the need for hardware upgrades, lightweight data processing, and data intelligence services. MicroAlgo’s ability to efficiently deliver software and hardware optimization to customers through bespoke central processing algorithms serves as a driving force for MicroAlgo’s long-term development.

Forward-Looking Statements

This press release contains statements that may constitute “forward-looking statements.” Forward-looking statements are subject to numerous conditions, many of which are beyond the control of MicroAlgo, including those set forth in the Risk Factors section of MicroAlgo’s periodic reports on Forms 10-K and 8-K filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, MicroAlgo’s expectations with respect to future performance and anticipated financial impacts of the business transaction.

MicroAlgo undertakes no obligation to update these statements for revisions or changes after the date of this release, except as may be required by law.